In a move signaling a strategic push toward late-stage development, Basking Biosciences has appointed Lance Berman as its new chief medical officer, the company announced today.
Berman joins from Pulmocide, where he served as CMO and led several respiratory drug programs. His mandate at Basking will be to oversee the clinical pipeline and accelerate regulatory submissions.
The Appointment
“Lance brings a proven track record in bringing novel therapies from Phase I through approval,” said a Basking spokesperson. “We are confident his leadership will be instrumental as we enter a pivotal phase.”
Berman replaces outgoing CMO Dr. Jane Doe, who left to pursue other opportunities. The transition is effective immediately.
Background
Basking Biosciences is a privately held biotech focused on oncology and rare diseases. In recent months, the company has raised Series C funding and initiated two Phase II trials.
Lance Berman previously spent five years at Pulmocide, where he oversaw the development of a novel antifungal treatment. Earlier roles included senior positions at Merck and GSK.
What This Means
The hiring is seen as a strategic move to strengthen R&D leadership ahead of key data readouts. Industry analysts say Berman’s expertise in respiratory indications could also signal a shift in Basking’s pipeline priorities.
“Bringing in a seasoned CMO like Berman suggests Basking is preparing for late-stage trials and potential commercialization,” said Dr. Emily Zhao, a biotech analyst at Leerink Partners. “Investors will be watching closely.”
Berman is expected to begin immediately and will be based in Basking’s Cambridge, Massachusetts headquarters.
This story is breaking and will be updated.